Cargando…
A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes
Despite the great success of CTLA-4 blocking in cancer treatment, the use of anti-CTLA-4 monoclonal antibodies still faces many limitations. Now, immune checkpoint blocking coupled with adoptive cell therapy is gaining much attention. In this paper, we reported a strategy on the basis of anti-CTLA-4...
Autores principales: | Yang, Wenli, Pang, Yanyang, Wang, Xi, Lai, Zhiheng, Lu, Yanda, Zheng, Shaojiang, Wang, Wu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328924/ https://www.ncbi.nlm.nih.gov/pubmed/37419930 http://dx.doi.org/10.1038/s41419-023-05914-w |
Ejemplares similares
-
Screening and antitumor effect of an anti-CTLA-4 nanobody
por: Wan, Ruirong, et al.
Publicado: (2018) -
A CTLA-4 blocking strategy based on Nanoboby in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects
por: Wang, Wu, et al.
Publicado: (2021) -
PD-1 blocking strategy for enhancing the anti-tumor effect of CAR T cells targeted CD105
por: Wang, Xi, et al.
Publicado: (2023) -
Developing and characterizing a single-domain antibody (nanobody) against human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4)
por: Sotoudeh, Nazli, et al.
Publicado: (2021) -
Dendritic cell-glioma fusion activates T lymphocytes by elevating cytotoxic efficiency as an antitumor vaccine
por: Tian, Fuming, et al.
Publicado: (2014)